LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Akcijų sąrašas・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Uždarymo kaina

29.45 2.12

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.72

Max

29.57

Pagrindiniai rodikliai
By Trading Economics
Pajamos	43M 13M
Pardavimai	29M 107M
Pelnas, tenkantis vienai akcijai	0.25
Pelno marža	12.139
Darbuotojai	524
EBITDA	16M 8.2M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+123.58% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	17M 1.5B
Ankstesnė atidarymo kaina	27.33
Ankstesnė uždarymo kaina	29.45

Immunocore Holdings PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-02 20:30; UTC

Uždarbis

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2026-06-02 23:58; UTC

Rinkos pokalbiai

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2026-06-02 23:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-02 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2026-06-02 23:41; UTC

Rinkos pokalbiai

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2026-06-02 23:01; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2026-06-02 23:01; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2026-06-02 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2026-06-02 22:57; UTC

Rinkos pokalbiai

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2026-06-02 22:50; UTC

Rinkos pokalbiai

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2026-06-02 21:07; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-02 21:07; UTC

Rinkos pokalbiai

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2026-06-02 21:00; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-02 20:46; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:38; UTC

Uždarbis

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2026-06-02 20:21; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:12; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Product Rev $594M

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Adj EPS 85c >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Loss $177M >PANW

Akcijų palyginimas

Kainos pokytis

Immunocore Holdings PLC ADR Prognozė

Kainos tikslas

By TipRanks

123.58% į viršų

12 mėnesių prognozė

Vidutinis 65.13 USD 123.58%

Aukščiausias 100 USD

Žemiausias 33 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Immunocore Holdings PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Immunocore Holdings PLC ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.